Search Within

Clifford Hudis

Formats
  1. Journal Article (484)
  2. Meeting Abstract (393)
  3. Book Section (15)
  4. Conference Paper (10)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Review (1)
Groups
  1. Breast Medicine Service (906)
  2. Department of Medicine (906)
  3. Solid Tumor Oncology Division (906)
  4. Survivorship Research (906)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (318)
  6. Epidemiology and Biostatistics (242)

More Groups

People
  1. Larry Norton (293)
  2. Sujata Patil (141)
  3. Andrew Seidman (116)
  4. Chau Dang (111)
  5. Maura Dickler (102)
  6. Tiffany Traina (95)

More People

Years
  1. 2025 (2)
  2. 2023 (1)
  3. 2022 (2)
  4. 2021 (4)
  5. 2020 (5)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (246)
  2. Cancer Research (108)
  3. Breast Cancer Research and Treatment (77)
  4. Clinical Cancer Research (33)
  5. Cancer (30)
  6. Annals of Oncology (29)

More Publications

Publishers
  1. American Society of Clinical Oncology (249)
  2. American Association for Cancer Research (163)
  3. Springer (100)
  4. Elsevier Inc. (84)
  5. Oxford University Press (55)
  6. Wiley Blackwell (45)

More Publishers

Results (906)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of a weight loss intervention on 1-year weight change in women with stage II/III breast cancer: Secondary analysis of the Breast Cancer Weight Loss (BWEL) trial
    Journal Article

    Ligibel, J. A.; Ballman, K. V.; McCall, L.; Goodwin, P. J.; Alfano, C. M.; Bernstein, V.; Crane, T. E.; Delahanty, L. M.; Frank, E.; Hahn, O.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
    Journal Article

    Metzger Filho, O.; Ballman, K.; Campbell, J.; Liu, M.; Ligibel, J.; Watson, M.; Chen, E.; Du, L.; Stover, D.; Carey, L.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: Final 10-year analysis of the open-label, single-arm, phase 2 APT trial
    Journal Article

    Tolaney, S. M.; Tarantino, P.; Graham, N.; Tayob, N.; Parè€, L.; Villacampa, G.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. K.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer
    Journal Article

    Shepherd, J. H.; Ballman, K.; Polley, M. Y. C.; Campbell, J. D.; Fan, C.; Selitsky, S.; Fernandez-Martinez, A.; Parker, J. S.; Hoadley, K. A.; Hu, Z.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention
    Review

    Delahanty, L. M.; Wadden, T. A.; Goodwin, P. J.; Alfano, C. M.; Thomson, C. A.; Irwin, M. L.; Neuhouser, M. L.; Crane, T. E.; Frank, E.; Spears, P. A.; more...
    Obesity (2022)

    Fulltext@MSK | Save
  • Physical activity, weight, and outcomes in patients receiving chemotherapy for metastatic breast cancer (C40502/Alliance)
    Journal Article

    Ligibel, J. A.; Huebner, L.; Rugo, H. S.; Burstein, H. J.; Toppmeyer, D. L.; Anders, C. K.; Ma, C.; Barry, W. T.; Suman, V.; Carey, L. A.; more...
    JNCI Cancer Spectrum (2021)

    Fulltext@MSK | Save
  • Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy
    Journal Article

    Magbanua, M. J. M.; Hendrix, L. H.; Hyslop, T.; Barry, W. T.; Winer, E. P.; Hudis, C.; Toppmeyer, D.; Carey, L. A.; Partridge, A. H.; Pierga, J. Y.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
    Meeting Abstract

    Ma, C. X.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)
    Meeting Abstract

    Ellis, M. J.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save